Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Clearside reports negative results from Phase III SAPPHIRE trial

Xipere can be administered to the back of the eye via the suprachoroidal space. Credit: William Warby.



  • Clearside Biomedical

Go Top